Intellia Therapeutics - investor relations

Skip to main navigation

invest in
partner in
join
- our dna
- we’re in
- i’m in
- join in
- benefits
info
CRISPR/CAS9
pipeline
get in touch
news & resources

stock information

Copyright West LLC. Minimum 15 minutes delayed.

press releases

–

Jun 26, 2019

Summary Toggle Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing Technology

events and presentation

There are currently no events to display.

corporate governance

corporate governance

financial information

financial information

stock<br />
information

stock
information

investor<br />
FAQs

investor
FAQs

information<br />
request

information
request

IR<br />
contacts

IR & Media
contacts

analyst coverage

invest in

Investor Relations

investor relations
press releases
events & presentations
corporate governance
financial information
stock information
analyst coverage
investor FAQs
information request
IR & Media Contacts

partner in

partnering
our partners
who to contact

join

we’re in
i’m in
join in

CRISPR/Cas9

transforming technology
how CRISPR/Cas9 works
strategy
types of edits
delivery of CRISPR/Cas9
engineered cell therapy

pipeline

info

overview
leadership
scientific advisors

get in touch

© Intellia Therapeutics 2019

terms of use

Menu